On March 17, 2022 Shasqi, a clinical-stage biotechnology company developing precision click chemistry-activated oncology therapeutics, reported that it will present updated data from its ongoing Phase 1 clinical study of SQ3370 in patients with advanced solid tumors as well as preclinical data highlighting the activity of its click chemistry-modified protodrug version of monomethyl auristatin E (MMAE), at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Shasqi, MAR 17, 2022, View Source [SID1234610286]). Presentations and posters will be available for registered attendees for on-demand viewing on the AACR (Free AACR Whitepaper) website on April 8, 2022, after 1:00 pm ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We continue to be encouraged by initial data observed from our ongoing Phase 1 study of SQ3370 in heavily pre-treated patients with high disease burden, and we are advancing the development of SQ3370 as a treatment for patients with advanced solid tumors where an anthracycline-containing regimen is appropriate," said José M. Mejía Oneto, M.D., Ph.D., founder and CEO of Shasqi. "We’ve also demonstrated that our click chemistry platform can activate high doses of MMAE, a commonly used antibody-drug conjugate payload, at the tumor. Our MMAE protodrug achieved good plasma stability, attenuation of cytotoxicity, and was tolerated at doses up to 50-fold higher than the conventional MMAE maximum tolerated dose. We also present the anti-tumor effect of MMAE protodrugs activated at the tumor site using a biopolymer injection. We look forward to studying the anti-tumor efficacy of MMAE protodrugs when targeted to the tumor using biologic approaches."
Preclinical Poster Title: Click Activated Protodrugs Against Cancer (CAPAC): A modular platform for tumor-directed oncology therapeutics
Session Title: New Technologies for Drug Discovery
Session Date and Time: Monday, April 11, 1:30-5:00 pm CST
Abstract Number: 1894/25
Poster Number: ET01/02
Trial-In-Progress Poster Title: SQ3370 in advanced solid tumors: Interim phase 1 results
Session Title: Phase 1 Clinical Trials 2
Session Date and Time: Tuesday, April 12, 9:00 am -12:30 pm CST
Abstract Number: CT177/2
Poster Number: CT01/02
About CAPAC and SQ3370:
SQ3370 is the first click chemistry-based treatment to be tested in humans. It utilizes Shasqi’s proprietary CAPAC platform, an approach that activates cancer drugs at a tumor with decreased systemic toxicity. Shasqi is validating its platform with SQ3370, which is designed to activate a powerful chemotherapeutic, doxorubicin, at the tumor site. The investigational product is based on the chemical reaction between a drug protected through a trans-cyclooctene modification (a protodrug) and a tetrazine-modified biopolymer. The biopolymer is injected into the target tumor lesion, where it precisely activates an intravenously infused protodrug. Shasqi believes its click-chemistry approach can improve the efficacy and safety of many existing therapeutics across various modalities that have a limited therapeutic window.